Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?

被引:28
|
作者
Lahat, G. [1 ,2 ]
Lubezky, N. [1 ,2 ]
Gerstenhaber, F. [1 ,2 ]
Nizri, E. [1 ,2 ]
Gysi, M. [2 ]
Rozenek, M. [2 ]
Goichman, Y. [1 ,2 ]
Nachmany, I. [1 ,2 ]
Nakache, R. [1 ,2 ]
Wolf, I. [2 ,3 ]
Klausner, J. M. [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Surg, 6th Weitzman St, Tel Aviv, Israel
[2] Tel Aviv Univ, Nicholas & Elizabeth Cathedra Expt Surg, Sackler Fac Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel
关键词
LONG-TERM SURVIVAL; EXTENDED LYMPHADENECTOMY; PROGNOSTIC-SIGNIFICANCE; CURATIVE RESECTION; CANCER; HEAD; PANCREATICODUODENECTOMY; IMPACT; CARCINOMA; METASTASES;
D O I
10.1186/s12957-016-0983-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We evaluated the prognostic significance and universal validity of the total number of evaluated lymph nodes (ELN), number of positive lymph nodes (PLN), lymph node ratio (LNR), and log odds of positive lymph nodes (LODDS) in a relatively large and homogenous cohort of surgically treated pancreatic ductal adenocarcinoma (PDAC) patients. Methods: Prospectively accrued data were retrospectively analyzed for 282 PDAC patients who had pancreaticoduodenectomy (PD) at our institution. Long-term survival was analyzed according to the ELN, PLN, LNR, and LODDS. Results: Of these patients, 168 patients (59.5 %) had LN metastasis (N1). Mean ELN and PLN were 13.5 and 1.6, respectively. LN positivity correlated with a greater number of evaluated lymph nodes; positive lymph nodes were identified in 61.4 % of the patients with ELN >= 13 compared with 44.9 % of the patients with ELN < 13 (p = 0.014). Median overall survival (OS) and 5-year OS rate were higher in N0 than in N1 patients, 22.4 vs. 18.7 months and 35 vs. 11 %, respectively (p = 0.008). Mean LNR was 0.12; 91 patients (54.1 %) had LNR < 0.3. Among the N1 patients, median OS was comparable in those with LNR = 0.3 vs. LNR < 0.3 (16.7 vs. 14.1 months, p = 0.950). Neither LODDS nor various ELN and PLN cutoff values provided more discriminative information within the group of N1 patients. Conclusions: Our data confirms that lymph node positivity strongly reflects PDAC biology and thus patient outcome. While a higher number of evaluated lymph nodes may provide a more accurate nodal staging, it does not have any prognostic value among N1 patients. Similarly, PLN, LNR, and LODDS had limited prognostic relevance.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma
    Zhao, Yue
    Li, Guodong
    Zheng, Difan
    Jia, Ming
    Dai, Weixing
    Sun, Yihua
    Chen, Haiquan
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 153 (03) : 702 - +
  • [2] A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma
    Elshaer, M.
    Gravante, G.
    Kosmin, M.
    Riaz, A.
    Al-Bahrani, A.
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2017, 99 (02) : 101 - 106
  • [3] The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer
    Olthof, Ester P.
    Mom, Constantijne H.
    Snijders, Malou L. H.
    Wenzel, Hans H. B.
    Velden, Jacobus
    Aa, Maaike A.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (05) : 550 - 557
  • [4] Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma
    Liu, Zu-Qiang
    Xiao, Zhi-Wen
    Luo, Guo-Pei
    Liu, Liang
    Liu, Chen
    Xu, Jin
    Long, Jiang
    Ni, Quan-Xing
    Yu, Xian-Jun
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2014, 13 (06) : 634 - 641
  • [5] Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic Carcinoma
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hayashidani, Yasuo
    Hashimoto, Yasushi
    Nakashima, Akira
    Yuasa, Yoshio
    Kondo, Naru
    Ohge, Hiroki
    Sueda, Taijiro
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 211 (02) : 196 - 204
  • [6] Number of Lymph Nodes Evaluated: Prognostic Value in Pancreatic Adenocarcinoma
    Huebner, Marianne
    Kendrick, Michael
    Reid-Lombardo, Kaye M.
    Que, Florencia
    Therneau, Terry
    Qin, Rui
    Donohue, John
    Nagorney, David
    Farnell, Michael
    Sarr, Michael
    JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 16 (05) : 920 - 926
  • [7] Lymph Node Ratio Versus Number of Affected Lymph Nodes as Predictors of Survival for Resected Pancreatic Adenocarcinoma
    Bhatti, Imran
    Peacock, Oliver
    Awan, Altaf K.
    Semeraro, David
    Larvin, Michael
    Hall, Richard I.
    WORLD JOURNAL OF SURGERY, 2010, 34 (04) : 768 - 775
  • [8] Revisiting the Concept of Lymph Node Metastases of Pancreatic Head Cancer: Number of Metastatic Lymph Nodes and Lymph Node Ratio According to N Stage
    Kang, Mee Joo
    Jang, Jin-Young
    Chang, Ye Rim
    Kwon, Wooil
    Jung, Woohyun
    Kim, Sun-Whe
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (05) : 1545 - 1551
  • [9] What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes
    Conci, S.
    Ruzzenente, A.
    Sandri, M.
    Bertuzzo, F.
    Campagnaro, T.
    Bagante, F.
    Capelli, P.
    D'Onofrio, M.
    Piccino, M.
    Dorna, A. E.
    Pedrazzani, C.
    Iacono, C.
    Guglielmi, A.
    EJSO, 2017, 43 (04): : 743 - 750
  • [10] A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
    Song, Yunda
    Chen, Zhenxin
    Chen, Luohai
    He, Chaobin
    Huang, Xin
    Duan, Fangting
    Wang, Jun
    Lao, Xiangming
    Li, Shengping
    JOURNAL OF CANCER, 2018, 9 (19): : 3507 - 3514